AMPH Stock News & Catalysts – Amphastar Pharmaceuticals

FEATURED

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2026

Net revenues of $207.6 million for the three months ended September 30, 2026GAAP net income of $37.8 million, or $0.87 per share, for the third quarterAdjusted non-GAAP net income of $49.3 million, or $1.14 per share,

Summary

Nov 5, 2026, 4:10 PM ·PRNewswire

RECENT

Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 5, 2026

RANCHO CUCAMONGA, Calif., October 29, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that the Company will release results for its third quarter of 2026 ended September 30, 2026,

Oct 29, 2026, 6:00 AM ·PRNewswire

Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference

RANCHO CUCAMONGA, Calif., Sept. 1, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be

Sep 1, 2026, 6:00 AM ·PRNewswire

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026

Net revenues of $183.9 million for the three months ended June 30, 2026GAAP net income of $30.3 million, or $0.67 per share, for the second quarterAdjusted non-GAAP net income of $40.8 million, or $0.91 per share, for

Aug 6, 2026, 4:05 PM ·PRNewswire

Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026

RANCHO CUCAMONGA, Calif., July 29, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that the Company will release results for its second quarter of 2026 ended June 30, 2026, after the

Jul 29, 2026, 6:00 AM ·PRNewswire

Amphastar Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) or certain of its executive officers violated federal securities laws. The

Jun 8, 2026, 8:19 AM ·Globe Newswire

Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESS Newswire / May 27, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will be presenting at

May 27, 2026, 6:00 AM ·ACCESS Newswire

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026

Net revenues of $171.2 million for the three months ended March 31, 2026GAAP net income of $6.4 million, or $0.14 per share, for the first quarterAdjusted non-GAAP net income of $19.5 million, or $0.42 per share, for the

May 7, 2026, 4:05 PM ·ACCESS Newswire

Amphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care Conference

RANCHO CUCAMONGA, CA / ACCESS Newswire / May 6, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be

May 6, 2026, 6:00 AM ·ACCESS Newswire

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7, 2026

RANCHO CUCAMONGA, CA / ACCESS Newswire / April 30, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that the Company will release results for its first quarter of 2026, ended March 31, 2026, after the

Apr 30, 2026, 6:00 AM ·ACCESS Newswire

Amphastar Pharmaceuticals to Present at the 25th Annual Needham Healthcare Conference

RANCHO CUCAMONGA, CA / ACCESS Newswire / April 6, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") announced today that Bill Peters, CFO, Tony Marrs, EVP of Regulatory Affairs and

Apr 6, 2026, 6:00 AM ·ACCESS Newswire

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025

Net revenues of $183.1 million and $719.9 million, respectively, for the three months and fiscal year ended December 31, 2025GAAP net income of $24.4 million, or $0.51 per share and $98.1 million, or $2.03 per share,

Feb 26, 2026, 4:05 PM ·ACCESS Newswire

Amphastar Announces FDA Approval for Ipratropium Bromide HFA

RANCHO CUCAMONGA, CA / ACCESS Newswire / February 24, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug

Feb 24, 2026, 6:00 AM ·ACCESS Newswire

Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 26, 2026

RANCHO CUCAMONGA, CA / ACCESS Newswire / February 20, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2025 ended December 31, 2025, after the

Feb 20, 2026, 6:00 AM ·ACCESS Newswire

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound

Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditionsRANCHO CUCAMONGA, CA / ACCESS Newswire / January 12, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Jan 12, 2026, 6:00 AM ·ACCESS Newswire

Amphastar Pharmaceuticals, Inc. AMPH · News